Absence of RET gene point mutations in sporadic thyroid C-cell hyperplasia

Section of Endocrinology, Department of Clinical and Biological Sciences, University of Turin, San Luigi Hospital, Orbassano, Italy.
Journal of Molecular Diagnostics (Impact Factor: 3.96). 05/2007; 9(2):214-9. DOI: 10.2353/jmoldx.2007.060166
Source: PubMed

ABSTRACT Progression from C-cell hyperplasia (CCH) to medullary thyroid carcinoma (MTC) has been demonstrated to date only in familial forms, whereas in nonfamilial MTC, such hypothesis is suggested by the rare concurrence of both lesions, although no epidemiological and molecular data are available to prove or disprove this event. Therefore, the clinical management of patients with sporadic CCH is controversial. To evaluate the malignant potential of sporadic CCHs, pure laser-microdissected C-cell populations of 24 CCH cases, either reactive or associated with nonfamilial MTC, were analyzed for MTC-associated protein neural cell adhesion molecule expression and RET point mutations in exons 10, 11, 15, and 16, by using immunohistochemistry and polymerase chain reaction-single-strand conformation polymorphism/heteroduplex electrophoresis/direct sequencing, respectively. No RET mutations were found in any of the 24 CCH cases, whereas M918T mutation was detected in three concomitant MTCs. Neural cell adhesion molecule was immunoreactive in the majority of CCH associated with MTC even in the absence of morphological atypia, but not in reactive forms. The absence of RET alterations in all cases of CCH examined supports the hypothesis that the development of MTC is independent of pre-existing CCH in the nonfamilial setting; thus, sporadic CCH should not be considered a risk factor for nonfamilial MTC.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Medullary thyroid carcinoma occurs in both sporadic (75%) and hereditary (25%) forms. The missense mutations of RET proto-oncogene in MTC development have been well demonstrated. To investigate the spectrum of predominant RET germline mutations in exons 10, 11, and 16 in hereditary MTC in Iranian population, 217 participants were included. Genomic DNAs were extracted from the leukocytes using the standard Salting Out/Proteinase K method. Mutation detection was performed through PCR-RFLP and DNA sequencing. In 217 participants, 43 missense mutations were identified in exons 10 (6%), 11 (13%), and 16 (0.9%). Moreover, a novel germline mutation was detected in exon 11 (S686N). Also four different polymorphisms were found in intron 16 in eight patients. The obtained data showed the frequency profile of RET mutations in Iranian individuals with MTC (19.8%). The most frequent mutation in our population was C634G whereas in most population it was C634R. Altogether, these results underline the importance of the genetic background of family members of any patient with MTC.
    06/2011; 2011:264248. DOI:10.4061/2011/264248
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: We aimed to assess RET proto-oncogene polymorphisms in three different Iranian families with medullary thyroid cancer (MTC), and performed molecular dynamics simulations and free energy stability analysis of these mutations. Materials and Methods: This study consisted of 48 patients and their first-degree relatives with MTC confirmed by pathologic diagnosis and surgery. We performed molecular dynamics simulations and free energy stability analysis of mutations, and docking evaluation of known RET proto-oncogene inhibitors, including ZD-6474 and ponatinib, with wild-type and mutant forms. Results: The first family consisted of 27 people from four generations, in which nine had the C.G2901A (P.C634Y) mutation; the second family consisted of six people, of whom three had the C.G2901T (P.C634F) mutation, and the third family, who included 12 individuals from three generations, three having the C.G2251A (P.G691S) mutation. The automated 3D structure of RET protein was predicted using I-TASSER, and validated by various protein model verification programs that showed more than 96.3% of the residues in favored and allowed regions. The predicted instability indices of the mutated structures were greater than 40, which reveals that mutated RET protein is less thermo-stable compared to the wild-type form (35.4). Conclusions: Simultaneous study of the cancer mutations using both in silico and medical genetic procedures, as well as onco-protein inhibitor binding considering mutation-induced drug resistance, may help in better overcoming chemotherapy resistance and designing innovative drugs.
    Asian Pacific journal of cancer prevention: APJCP 03/2014; 15(5):2027-33. DOI:10.7314/APJCP.2014.15.5.2027 · 1.50 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Das autosomal-dominant vererbte Syndrom der multiplen endokrinen Neoplasien vom Typ2 (MEN2) zeigt die Hauptkomponenten medulläres Schilddrüsenkarzinom, Phäochromozytom und Hyperparathyreoidismus. Klinisch werden aufgrund der beteiligten Tumoren und des biologischen Verlaufs drei distinkte Subtypen unterschieden (MEN2A, MEN2B, familiäres medulläres Schilddrüsenkarzinom). Die Erkrankung wird durch Keimbahnmutationen des RET-Protoonkogens ausgelöst, wobei die Lokalisation der jeweils vorliegenden Mutation am Gen mit dem zeitlichen Auftreten des den Krankheitsverlauf bestimmenden medullären Schilddrüsenkarzinoms korreliert und daher enormen Einfluss auf das Management der betroffenen Patienten und deren Angehörigen hat. Im vorliegenden Übersichtsartikel werden die Morphologie und Klinik der MEN2-assoziierten Tumoren und ihrer Vorläuferläsionen zusammengefasst. Multiple endocrine neoplasia type 2 (MEN 2) is an autosomal dominant inherited cancer syndrome with the major components medullary thyroid carcinoma, pheochromocytoma and hyperparathyroidism. Due to the clinical course three distinct subtypes are distinguished, MEN 2A, MEN 2B and familial medullary thyroid carcinoma. The disease is caused by germ-line mutations of the RET proto-oncogene and the localization of these mutations correlates with the onset of the development of medullary thyroid carcinoma, which is crucial for the clinical course and outcome of the disease. It therefore has a substantial influence on the clinical management of the affected patients and their relatives. This review summarizes the morphology and clinic of MEN 2-associated tumors and their respective precursor lesions. SchlüsselwörterMultiple endokrine Neoplasien–Medulläres Schilddrüsenkarzinom–Phäochromozytom–Hyperparathyreoidismus–Hirschsprung-Erkrankung KeywordsMultiple endocrine neoplasia–Medullary thyroid carcinoma–Pheochromocytoma–Hyperparathyroidism–Hirschsprung’s disease
    Der Pathologe 10/2010; 31(6):449-454. DOI:10.1007/s00292-010-1389-8 · 0.64 Impact Factor